Vaccines, Blood & Biologics
Resources for You
STN: BL 125284
Proper Name: Antithrombin (Recombinant)
Manufacturer: GTC Biotherapeutics, Inc., License # 1794
Indication: Antithrombin (Recombinant) is indicated for the prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
FDA Approves Orphan Drug ATryn to Treat Rare Clotting Disorder[ARCHIVED]
Press Release Dated: February 6, 2009